Altimmune reported that the 2.4mg pemvidutide arm of a mid-stage trial in people with moderate-to-severe alcohol-use disorder reduced heavy-drinking days significantly more than placebo and met the study's primary endpoint, making this a company readout rather than a published treatment recommendation. [1]

That boundary follows the paper's May 21 account that kept a different alcohol-use-disorder drug inside its trial design, because the earlier semaglutide study had its own 108-person population and obesity eligibility and none of its denominator, effect, or safety data can be borrowed for pemvidutide.

Reuters does not supply this trial's enrollment, absolute reduction in heavy-drinking days, confidence interval, retention, adverse events, discontinuations, abstinence result, or missing-data rules, so statistical significance alone cannot establish how large, durable, safe, or clinically meaningful the difference was. [1]

Altimmune said it plans to seek a meeting with the Food and Drug Administration, which is a proposed regulatory discussion rather than a phase 3 program, filing, approval, price, or access decision. [1]

Reuters leads with a sponsor-reported mid-stage endpoint while no topical X evidence was recovered, but the protocol and full results on sample, randomization, duration, baseline drinking, endpoint definition, secondary outcomes, and safety by arm are still needed before independent replication, treatment advice, or any recovery outcome.

-- NORA WHITFIELD, Chicago